Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Australian Clinical Labs Ltd ( (AU:ACL) ).
Australian Clinical Labs Ltd has announced an update regarding its ongoing share buy-back program. As of the latest notification, the company has repurchased a total of 5,692,629 ordinary fully paid securities, including 250,000 bought back on the previous day. This buy-back initiative is part of the company’s strategy to optimize its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Ltd operates in the healthcare industry, primarily focusing on providing pathology services. The company is known for its diagnostic testing and laboratory services, catering to the Australian market.
Average Trading Volume: 1,055,636
Technical Sentiment Signal: Sell
Current Market Cap: A$581M
For a thorough assessment of ACL stock, go to TipRanks’ Stock Analysis page.